Avenzo Therapeutics

Potential first-in-class data presentation for bispecific Nectin-4/TROP2 ADC

Avenzo Therapeutics today announced the appointment of Herb Cross as Chief Financial Officer (CFO), effective as of his employment start date (which is expected to be October 12, 2026).

Appoints Annie Chang as Senior Vice President of Investor Relations and Corporate Communications and Aaron Hasnain as Senior Vice President of Business Development

Avenzo Therapeutics announced acceptance of an abstract for a poster presentation at the 38th Symposium on Molecular Targets and Cancer Therapeutics, hosted by the EORTC, NCI, and AACR.

Aaron Hasnain serves as Senior Vice President, Business Development at Avenzo Therapeutics. He brings almost 15 years of progressive business development, strategic partnership, and alliance management experience in the biotechnology industry.

Annie Chang, M.B.A., serves as Senior Vice President of Investor Relations and Corporate Communications at Avenzo Therapeutics. She has over 20 years of experience in biotechnology, technology, and finance, including roles in investment banking, investment management, corporate development, and public company investor relations.

Barbara Bodem has over 30 years of experience as a business leader and board director in healthcare. She serves on the boards of BioMarin Pharmaceutical, Enovis Corporation, Option Care Health, BiomEdit, LLC, and NorthStar Medical Radioisotopes, and is a board of trustees member of the Nature Conservancy of Indiana.

Elizabeth A. Mily has more than 30 years of experience across the healthcare and financial services sectors. She currently serves as a director of Solventum Corporation and Ampersand Biomedicines.

Avenzo Therapeutics

Developing the next generation of oncology therapies for patients.

Avenzo Therapeutics explains its practices for collecting and processing personal data through its website, products, services, and interactions with users.

Avenzo Therapeutics reports updated Phase 1 data for **AVZO-021**, a CDK2-selective inhibitor, showing clinical activity in heavily pretreated patients with **hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer**. The findings were presented at the **2026 American Society of Clinical Oncology (ASCO) Annual Meeting**. The study remains ongoing, evaluating safety and efficacy in this patient population.

Jun 2026Avenzo Therapeutics | Developing the next generation of oncology therapies for patients.News article

Rallybio acquires Avenzo Therapeutics, a clinical-stage biotech firm specializing in next-generation oncology treatments. The merger combines their pipelines under the new name **Avenzo Therapeutics**, which will list on Nasdaq as **AVZO**. The deal includes a **$215 million private placement** and is set to close in **Q4 2026** after an announcement on **June 1, 2026**.

Jun 2026ropesgray.comNews article

Avenzo Therapeutics secures $60 million in Series B funding. The round is led by OrbiMed and SR One, with participation from existing investors and the new institutional investor Longwood Fund. The financing supports the company’s growth in biopharmaceutical development.

Sep 2025Avenzo Therapeutics | Developing the next generation of oncology therapies for patients.News article

Avenzo Therapeutics receives recognition from Goldman Sachs at the 2024 Builders and Innovators Summit. Athena Countouriotis, M.D., the company’s CEO, is among the honorees for her entrepreneurial contributions. The summit celebrates outstanding leaders in innovation and business development.

Oct 2024Avenzo Therapeutics | Developing the next generation of oncology therapies for patients.News article